Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Nizatidine is a histamine H2 antagonist with actions and uses similar to those of cimetidine. It inhibits gastric acid secretion and pepsin production. It is used in peptic ulcer and gastroesophageal reflux. Oral or parenteral administration once or twice daily.
It is excreted in breast milk in a clinically insignificant amount and no problems have been observed in the infant whose mother had taken it. (Obermeyer 1990)
Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Hale, Briggs 2015, Rowe 2013, Mahadevan 2006, Richter 2005, Nice 2000, Lee 1993)
Famotidine and Nizatidine are excreted into milk but in less proportion than Cimetidine or Ranitidine, which have been proposed as alternative to during lactation. (Rowe 2013, Nice 2000, Hagemann 1998, Lee 1993)